Living up to Our Students’ Expectations – Using Student Voice to Influence the Way Academics Think about Their Undergraduates Learning and Their Own Teaching von Wharton, Cecilia Yvette, Goodwin, Lorna J., Cameron, Andrea J.

Volltext

When can we trust structural models derived from pair distribution function measurements? von Maffettone, Phillip M, Fletcher, William J K, Nicholas, Thomas C, Deringer, Volker L, Allison, Jane R, Smith, Lorna J, Goodwin, Andrew L

Volltext

Impact of alemtuzumab-mediated lymphocyte depletion on SIV reservoir establishment and persistence von Varco-Merth, Benjamin, Chaunzwa, Morgan, Duell, Derick M, Marenco, Alejandra, Goodwin, William, Dannay, Rachel, Nekorchuk, Michael, Shao, Danica, Busman-Sahay, Kathleen, Fennessey, Christine M, Silipino, Lorna, Hull, Michael, Bosche, William J, Fast, Randy, Oswald, Kelli, Shoemaker, Rebecca, Bochart, Rachele, MacAllister, Rhonda, Labriola, Caralyn S, Smedley, Jeremy V, Axthelm, Michael K, Davenport, Miles P, Edlefsen, Paul T, Estes, Jacob D, Keele, Brandon F, Lifson, Jeffrey D, Lewin, Sharon R, Picker, Louis J, Okoye, Afam A

Volltext

Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models von Hopcroft, Lorna, Wigmore, Eleanor M., Williamson, Stuart C., Ros, Susana, Eberlein, Cath, Moss, Jennifer I., Urosevic, Jelena, Carnevalli, Larissa S., Talbot, Sara, Bradshaw, Lauren, Blaker, Catherine, Gunda, Sreeharsha, Owenson, Venetia, Hoffmann, Scott, Sutton, Daniel, Jones, Stewart, Goodwin, Richard J. A., Willis, Brandon S., Rooney, Claire, de Bruin, Elza C., Barry, Simon T.

Volltext

Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre,... von Cappel-Porter, Heike, Culliford, Lucy, Emmett, Stevan R, Hutton, David, Jacobsen, Nick, Joyce, Katherine, Kaminski, Rachel, Libri, Vincenzo, Middleditch, Alex, McCullagh, Liz, Moran, Ed, Thirard, Russell, Snape, Matthew D, Finn, Adam, Rogers, Chris A, Adams, Kirsty, Alaee, Seema, Aley, Parvinder K., Allum, Emma, Anthony, Sally, Awal, Tanya, Barron, Charlotte, Bennett, Lorna, Bishop, Sarah, Bodalia, Pritesh, Bowyer, Catherine, Bray, Jonathan J.H., Burge, Sharon, Chohan, Gurjit, Close, Adrianne, Coleman, Tom, Cowley, Claire, Cranfield, Charlotte, Cross, Eleanor, D'Arcangelo, Silvia, David Otter, Ashley, Davies, Kate, Davies, Louisa, Driver, Kimberley, Evans, Mim, Evans, Isabel, Feltham, Sally, Ford, Jamie, Gooch, Karen E., Goodwin, Jayne, Halliday, Alice, Harrhy, Sarah, Haxton, Lesley, Haynes, Matthew, Hazell, Mae, Hembrough, Tracey, Hewson, Jacqueline, Hicks, Bethany, Hill, Michelle, Hills, Alex, Hua, Cheryl, Iftikhar, Hina, Iqbal, Attya, Jones, Nicola, Kellett Wright, Johanna, Kidd, Sarah, Knibbs, Lucy, Langton, Helen, Lewis-Clarke, Phoebe, Maclean, Kirsty, Manning, Nicola, Marriott, Anthony, McFadzean, Isobel Joy, McLaughlin, Maeve, Mills, Bianca, Norman, Chris, Nyland, Kerry, Owen, Diana, Paterson, Jemma, Pegler, Suzannah, Rampling, Tommy, Rea, David, Regan, Karen, Riaz, Tawassal, Ricamara, Marivic, Rice, Danielle, Roots, Marianne, Salem, Ahmed, Salter-Hewitt, Jade, Shankland, Sara, Silva, Louise, Smith, Joyce, Stringer, Rebecca, Talbot, Helen, Taylor, Sarah Louise, Thomas, Amy, Tilzey, Grace, Turner, Kelly, Tyler, Jenny, Wale, Katharine, Warnes, Barbara, Whittley, Sarah, Williams, Jennie, Williamson, Kevin, Yim, Yee Ting Nicole

Volltext

Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models von Hopcroft, Lorna, Wigmore, Eleanor M., Williamson, Stuart C., Ros, Susana, Eberlein, Cath, Moss, Jennifer I., Urosevic, Jelena, Carnevalli, Larissa S., Talbot, Sara, Bradshaw, Lauren, Blaker, Catherine, Gunda, Sreeharsha, Owenson, Venetia, Hoffmann, Scott, Sutton, Daniel, Jones, Stewart, Goodwin, Richard J. A., Willis, Brandon S., Rooney, Claire, de Bruin, Elza C., Barry, Simon T.

Volltext

Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models von Hopcroft, Lorna, Wigmore, Eleanor M., Williamson, Stuart C., Ros, Susana, Eberlein, Cath, Moss, Jennifer I., Urosevic, Jelena, Carnevalli, Larissa S., Talbot, Sara, Bradshaw, Lauren, Blaker, Catherine, Gunda, Sreeharsha, Owenson, Venetia, Hoffmann, Scott, Sutton, Daniel, Jones, Stewart, Goodwin, Richard J. A., Willis, Brandon S., Rooney, Claire, DeBruin, Elza, Barry, Simon T.

Volltext